BeyondSpring Pharmaceuticals Inc.
Quick facts
Marketed products
- Docetaxel (D) · Oncology
Docetaxel stabilizes microtubules by binding to β-tubulin, preventing their depolymerization and causing cell cycle arrest and apoptosis in rapidly dividing cancer cells.
Phase 3 pipeline
- Docetaxel + Plinabulin (DP) · Oncology
Docetaxel inhibits microtubule depolymerization to arrest cell division, while plinabulin disrupts microtubule dynamics and suppresses neutrophil migration to enhance chemotherapy efficacy and reduce chemotherapy-induced neutropenia.
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: